Burjeel Medical City becomes the first member of the WIN Consortium in the Gulf region

UAE – Burjeel Medical City, the largest medical care facility of Burjeel Holdings, has become a member of the Worldwide Innovative Networking in Personalised Cancer Medicine (WIN) Consortium.

Prof. Humaid Al Shamsi, Director of Oncology Services at Burjeel Holdings, and Dr. Khaled Musallam, Group Chief Research Officer of Burjeel Holdings, have been appointed as the Group’s official representatives in the WIN Consortium.

On an official note, the WIN Consortium welcomed Burjeel Medical City as the first member hospital located in the United Arab Emirates and Gulf Cooperation Council countries.

“Burjeel Medical City’s expertise and resources in oncology and the Group’s scale of operations in the Middle East will be invaluable in our collaborative research efforts to advance personalised cancer medicine at the global level,” commented Dr. Richard L. Schilsky, Chairman of the WIN Consortium.

Burjeel Medical City is the newest member of the globally renowned network comprising over 30 elite organisations from the Americas, European Union, and Asia specialising in cancer care and research.

Inclusion in the WIN Consortium reinforces Burjeel Medical City’s commitment to developing targeted cancer therapeutics, aligning strategically with WIN’s mission.

It represents an interactive scientific platform for Burjeel Medical City to work closely with an exclusive network of experts involved in the patient journey and personalised cancer care.

WIN’s strategy is to perform innovative trials that explore novel strategies and tools to increase the efficacy of precision oncology for advanced cancers and improve early diagnosis.

“We are deeply honoured to join the WIN Consortium, which is at the forefront of research in personalised cancer medicine,” Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, said in a statement.

The consortium relies on genetically informed healthcare to accelerate the discovery and development of highly specialised cancer therapies.

For this reason, Burjeel Medical City is a natural fit for the WIN Consortium as the two entities share a common goal of improving cancer patients’ survival and quality of life.

It is in agreement with Burjeel Medical City’s mission to become the regional hub for cancer care, consistently accelerating research and innovation initiatives.

“The WIN Consortium provides a unique platform for us to share knowledge, expertise, and data to accelerate the development of innovative solutions and new treatments,” she outlined.

As part of the WIN Consortium, the medical healthcare facility has an innovative platform to strengthen its position as a pioneer in personalised cancer medicine in the UAE and the wider region.

This affiliation comes as the healthcare provider continues to embark on expansion plans to grow its network and expertise in the field of oncology.

Burjeel Medical City launched global clinical trials in Abu Dhabi to develop new treatments for thalassaemia, a group of inherited blood disorders that affect the body’s production of hemoglobin and red blood cells.

The trials will be conducted in collaboration with several centres and multiple sites across the United States of America, the European Union, and Asia.

To advance personalised medicine, Burjeel Holdings has made huge investments to provide advanced molecular genetics, cellular, and immunological profile testing to patients in the UAE.

“Through this new membership in the WIN Consortium, we will build on our commitment to providing the best possible care to our patients in the UAE and wider region,” stated Dr. Shamsheer Vayalil.

Situated in Mohammed Bin Zayed City, the medical facility is uniquely positioned to contribute to the future achievements of the WIN Consortium including breakthroughs in innovative cancer research.

The quaternary care centre based in Abu Dhabi has a diverse pool of patients that can contribute significantly to the collective group’s clinical studies in precision medicine.

What’s more, Burjeel Medical City joining the Worldwide Innovative Networking in Personalised Cancer Medicine Consortium will create opportunities for future collaborations across WIN programmes and projects.

“We look forward to collaborating with an elite global team to advance the understanding and treatment of cancer in an era of personalised care,” added Dr. Vayalil.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.